Custom Report

La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

More info

  • Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemoglobin
  • Approximately 80-95 percent editing was achieved in CD34+ cells
  • Increased fetal hemoglobin levels were sustained for at least 16 weeks following transplant in mice

ATLANTA, GA, USA I December 11, 2017 I Intellia Therapeutics, Inc. ( NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using the CRISPR technology, and its collaborator, Novartis, presented initial data from their research collaboration on genome-edited human hematopoietic stem cells. These data showed successfulex vivo editing of the erythroid specific enhancer of BCL11A, a gene associated with prevention of sickle cell disease, and the ability of these cells to stably engraft in mice while maintaining their desired properties.

These data were presented today at the American Society of Hematology Annual Meeting in the platform presentation session: Hemoglobinopathies, Excluding Thalassemia – Basic and Translational Science: Sickle Cell Disease – Hematopoiesis and Fetal Hemoglobin Augmentation . In the presented studies, the companies:

  • Achieved approximately 80-95 percent target site modification in human hematopoietic stem and progenitor CD34+ cells following electroporation of ribonucleoprotein (RNP) composed of Cas9 and a guide RNA (gRNA), selected for efficacy and potency;
     
  • Demonstrated an approximately 40 percent reduction in BCL11A mRNA with a corresponding two-fold increase in γ-globin transcript and 30-40 percent more fetal hemoglobin-positive cells above background. Similar decreases in BCL11A mRNA and increases in γ-globin transcipt were observed when sickle cell disease-derived cells from patient donors were edited;
     
  • Achieved engraftment over 16 weeks following transplantation of edited human bone marrow CD34+ cells into immune compromised mice, while maintaining editing levels in engrafted cells; and
     
  • Observed no off-target events in CD34+ cells edited with the selected gRNA, as measured by targeted next generation sequencing of sites identified through in silico prediction and based on an unbiased, genome-wide, oligo-insertion detection method.

“We are pleased to be reporting data from studies generated through Intellia’s collaboration with Novartis, demonstrating successful ex vivo CRISPR/Cas9 editing in hematopoietic stem cells,” said John Leonard, M.D., executive vice president, Research & Development, Intellia Therapeutics. “These results are significant as we have shown high levels of editing as well as increased production of fetal hemoglobin to clinically relevant levels, which could potentially ameliorate sickle cell disease in affected patients. We are very encouraged to present this progress given that sickle cell disease is a serious condition that currently has limited treatment options.”

About Sickle Cell Disease

Sickle cell disease is a life-threatening, hereditary disorder that impacts approximately 30 million people worldwide. The disease results from a single amino acid change in the β-globin gene, which causes polymerization of hemoglobin and the deformation of red blood cells, leading to vaso-occlusion, severe pain crisis and multi-organ dysfunction. The average life expectancy in the developed world is 40 to 60 years. About 80 percent of sickle cell disease cases are believed to occur in sub-Saharan Africa.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

SOURCE: Intellia Therapeutics
Post Views: 21